CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Febuxostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01763996
NCT01763996Phase 4Completed

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Subjects With Chronic Stable Angina: A Phase 4 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study

Takeda·interventional·Posted Jan 9, 2013·Updated Apr 13, 2016

In Brief

A Phase 4 clinical trial evaluating Febuxostat and Febuxostat placebo for Coronary Artery Disease. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effect of febuxostat on coronary artery flow in patients with coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 9, 2013
Enrollment StartMay 1, 2013
Primary CompletionMar 1, 2015
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.5 years ago

Interventions

Febuxostatdrug

Febuxostat capsules

Febuxostat placebodrug

Febuxostat placebo-matching capsules